Furaprofen is an orally available, selective and potent HCV inhibitor with anti-inflammatory activity, inhibits carrageenan-induced paw edema in rats and inhibits cotton pellet-induced granulomas in rats at higher doses.

HCV 1a/1b:（EC50）~30 nM, HCV 2a:~1000 nM（EC50）

The effectiveness of Furaprofen in inhibiting the replicon is verified through Western blotting and TaqMan RT-PCR, yielding IC50 values of approximately 37 nM and 54.67±4.11 nM, respectively. Furthermore, its antiviral potency, assessed via a reporter replicon assay conducted through multiple iterations, demonstrates a significant increase, standing at 29.88±8.05 nM—indicating an approximately threefold enhancement when compared to its precursor compound, R706. To evaluate Furaprofen's broader impact on cell proliferation, diverse primary and transformed human cell lines were subjected to escalating doses of the compound over a 48-hour period. The resultant effect on cell proliferation was quantified using an MTS-based cell viability assay, revealing the CC50 (the concentration required to diminish cell numbers by 50% in the absence of viral infection) of Furaprofen to vary between 2 μM and ≥10 μM, contingent upon the specific cell type and its proliferation state[1].